Wednesday, 22 January 2020

Roche's risdiplam meets primary endpoint in trial of SMA drug in infants

Roche's risdiplam met the primary endpoint in a pivotal clinical trial in infants with type 1 spinal muscular atrophy, the Swiss drugmaker said on Thursday.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)